Drugs / Robatumumab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00960063 | Nov 2009 → Dec 2010 | bone cancer, kidney neoplasm, neuroblastoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00954512 | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00617890 | Feb 2008 → Aug 2011 | Ewing sarcoma, osteosarcoma, peripheral primitive neuroectodermal tumor | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00551213 | Nov 2007 → Jun 2009 | colorectal cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Robatumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00960063 ↗ |
| Known as | 19D12 | “Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R).” PMID 27362300 ↗ Jun 2016 |
| Known as | MK-7454 | “A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)” NCT00551213 ↗2“Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens” NCT00954512 ↗ “robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy” NCT00960063 ↗ |
| Known as | SCH717454 | “Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R).” PMID 27362300 ↗ Jun 20163“A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)” NCT00551213 ↗ “Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens” NCT00954512 ↗ “robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy” NCT00960063 ↗ |
| Action | Inhibit | “IGF-1R antagonist robatumumab” PMID 24905030 ↗ Jun 2014 |
| Modality | Monoclonal antibody | “monoclonal antibody robatumumab (SCH 717454)” PMID 24905030 ↗ Jun 2014 |
| Route | Intravenous | “Robatumumab IV every two weeks until disease progression.” NCT00617890 ↗ |
| Target | IGF1R | “Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R).” PMID 27362300 ↗ Jun 2016 |